TerminatedPhase 1NCT00725062

Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant

Studying Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Masonic Cancer Center, University of Minnesota
Principal Investigator
Margaret L. MacMillan, MD, PA-C
Masonic Cancer Center, University of Minnesota
Intervention
CD4+CD25+ regulatory T cells(biological)
Enrollment
3 enrolled
Eligibility
18-70 years · All sexes
Timeline
20082010

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00725062 on ClinicalTrials.gov

Other trials for Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

Additional recruiting or active studies for the same condition.

See all trials for Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement

← Back to all trials